Matsu****a says new DNA technology identifies disease risks
http://www.physorg.
com/news13843756 0.html
Japan's Matsu****a Electric Industrial Co. said Wednesday that it had
developed a new way of predicting from a person's DNA their response
to medication and risk of developing disease.
Matsu****a, which is best known for its Panasonic brand, said it had
developed a technology to electronically identify sequence variations
in DNA, called single nucleotide polymorphisms, or SNPs.
It described the technology as a "world-first" that uses artificial
DNA dissolved in a solution instead of being attached to an electrode.
"This technology makes it possible to predict individuals' responses
to drugs and their risk of developing disease," said the company,
which collaborated with Konan University on the project.
"In the future, this technology is expected to enable hospitals or
clinics to provide patients with treatments and drugs tailored to
their individual physical characteristics, " it said.
